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Background: Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited genetic
disorder characterized by recurrent and chronic open wounds with signiﬁcant morbidity,
impaired quality of life, and early mortality. RDEB patients demonstrate reduction or
structural alteration type VII collagen (C7) owing to mutations in the gene COL7A1, the
main component of anchoring ﬁbrils (AF) necessary to maintain epidermal-dermal cohesion.
While over 700 alterations in COL7A1 have been reported to cause dystrophic epidermolysis
bullosa (DEB), which may be inherited in an autosomal dominant (DDEB) or autosomal
recessive pattern (RDEB), the incidence and prevalence of RDEB is not well deﬁned. To
date, the widely estimated incidence (0.2–6.65 per million births) and prevalence (3.5–20.4 -
per million people) of RDEB has been primarily characterized by limited analyses of clinical
databases or registries.
Methods: Using a genetic modelling approach, we use whole exome and genome sequen-
cing data to estimate the allele frequency of pathogenic variants. Through the ClinVar and
NCBI database of human genome variants and phenotypes, DEB Register, and analyzing
premature COL7A1 termination variants we built a model to predict the pathogenicity of
previously unclassiﬁed variants. We applied the model to publicly available sequences from
the Exome Aggregation Consortium (ExAC) and Genome Aggregation Database (gnomAD)
and identiﬁed variants which were classiﬁed as pathogenic for RDEB from which we
estimate disease incidence and prevalence.
Results: Genetic modelling applied to the whole exome and genome sequencing data
resulted in the identiﬁcation of predicted RDEB pathogenic alleles, from which our estimate
of the incidence of RDEB is 95 per million live births, 30 times the 3.05 per million live birth
incidence estimated by the National Epidermolysis Bullosa Registry (NEBR). Using
a simulation approach, we estimate a mean of approximately 3,850 patients in the US who
may beneﬁt from COL7A1-mediated treatments in the US.
Conclusion: We conclude that genetic allele frequency estimation may enhance the under-
diagnosis of rare genetic diseases generally, and RDEB speciﬁcally, which may improve
incidence and prevalence estimates of patients who may beneﬁt from treatment.
Keywords: Dystrophic Epidermolysis Bullosa, genotype, phenotype, incidence, prevalence
Background
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited genetic disorder
characterized by recurrent and chronic open wounds with signiﬁcant morbidity,
impaired quality of life, and early mortality. RDEB patients lack functional type VII
collagen (C7) owing to mutations in the gene COL7A1, the main component of
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anchoring ﬁbrils (AF) necessary to maintain epidermal-
dermal cohesion. While over 700 alterations in COL7A1
have been reported to cause Dystrophic epidermolysis bul-
losa (DEB), which may be inherited in an autosomal domi-
nant or autosomal recessive pattern,1 the incidence and
prevalence of RDEB are not well deﬁned. To date, the widely
estimated incidence (0.2–6.65 per million births) and preva-
lence (3.5–20.4 per million people) of RDEB has been pri-
marily characterized by limited analyses of clinical databases
or registries (Table 1).
Of note, patients face signiﬁcant cost and delays in
receiving an accurate and timely diagnosis due to the
cost and availability of genetic testing, as well as
a limited number of rare disease specialists. In the US,
rare disease patients visit an average of 7.3 physicians over
7.6 years before receiving a diagnosis.2,3 Also, a growing
number of population genome sequencing efforts such as
the 100,000 Genome Project in the UK are highlighting
cases of missed diagnoses and developing more accurate
genotype-phenotype correlations,4 including mutations
associated with various degrees of pathogenicity.5 In this
context, we explore whether genetic allele frequency esti-
mation may enhance the under-diagnosis of rare genetic
diseases generally, and RDEB speciﬁcally, towards
improving the incidence and prevalence estimates of
patients who may beneﬁt from treatment.
Using a genetic modelling approach, we use whole
exome and genome sequencing data to estimate the allele
frequency of recessive pathogenic variants in the COL7A1
gene. Through ClinVar, the NCBI database of human
genome variants and phenotypes, DEB Register, and ana-
lyzing premature COL7A1 termination variants, we identi-
ﬁed 270 variants with documented clinical signiﬁcance.
From these, we built a model to predict the pathogenicity
of previously unclassiﬁed variants. Applying the model to
variant data in the Exome Aggregation Consortium
(ExAC) database and the Genome Aggregation Database
(gnomAD) in Appendix A, we identiﬁed the aggregate
frequency of variants predicted to be pathogenic for
RDEB and estimated the incidence of the disease.
Dystrophic Epidermolysis Bullosa (DEB)
Dystrophic epidermolysis bullosa (DEB) is one of four major
types of epidermolysis bullosa (EB), a group of genetic
disorders of the skin and mucous membranes which arise
from the defects of basal keratinocyte attachment to the
underlying dermis. The skin layer in which the separation
occurs deﬁnes the EB type. In DEB, separation occurs in the
sublamina densa, which attaches the epidermis to the papil-
lary dermis. The separation results from reduction or altera-
tion of C7, a major component of the anchoring ﬁbrils that
mediate dermal-epidermal cohesion.1,6
Gene and Protein
Structure
The gene that encodes C7 is COL7A1. Each C7 molecule is
composed of 3 procollagen α1 chains; each procollagen chain
contains 3 domains: an amino-terminal noncollagenous
domain (NC1), a central collagenous, triple-helical domain,
and a carboxyl-terminal noncollagenous domain (NC2).
Genetics
Over 700 alterations in COL7A1 have been reported to cause
DEB, which may be inherited in an autosomal dominant or
autosomal recessive pattern.7 Less common genetic mechan-
isms have also been observed. A patient carrying only one
COL7A1 mutation not present in the parents’ peripheral
blood leukocytes suggested de novo mutation or parental
germline mosaicism. Such cases recurred in at least one
Table 1 Reported Incidence and Prevalence of Dystrophic
Epidermolysis Bullosa
Country DEB Subtype Incidence* Prevalence**
United States14 DEB, All 6.65 3.26
United States14 DDEB, All 2.12 1.49
United States14 RDEB, All*** 3.05 1.35
United States14 RDEB-GS 0.57 0.36
United States14 RDEB-GI (RDEB-
GO)
0.30 0.14
United States14 RDEB-Unknown 1.93 0.69
United States14 DEB, Unknown
mode
1.48 0.42
Northern
Ireland11
DEB, All 0.3 3.0
Northern
Ireland11
DDEB, All 0.15 1.5
Northern
Ireland11
RDEB, All 0.15 1.5
Croatia16 RDEB-GS 19 6.1
Croatia16 DDEB 4 0.43
Scotland15 DEB, All 0.2 20.4
Scotland15 DDEB – 14.6
Scotland15 RDEB-GS – 0.8
Spain17 DEB, All (adults) – 6.0
Spain17 DEB, All
(children)
– 15.3
Notes: *Per 1 million live births. **Per 1 million people. ***Includes rare subtypes
not listed in the table.
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family, strongly suggesting parental mosaicism.8 In two
cases with apparently recessive inheritance, only one hetero-
zygous mutation was detected after sequencing all 118 exons
and ﬂanking exon–intron borders, while the parent carrying
the identiﬁed mutation was unaffected.9 Finally, one case of
RDEB-GS was homozygous for a frameshift mutation,
345insG, carried by the mother due to maternal isodisomy
of chromosome 3.8 Most mutations are family-speciﬁc, but
a few recurrent mutations have been noted.6,8
RDEB Subtypes
Individuals with RDEB-GS produce little to no C7. They
frequently have two COL7AI alleles with premature stop
codons, resulting in mRNA decay, absence of mRNA
expression, or formation of truncated C7 polypeptides
that are structurally defective or rapidly degraded in
cells. They often have generalized blistering from birth
that results in extensive scarring, and alopecia. Patients
with RDEB-GS also suffer from extracutaneous manifes-
tations, resulting in an increased risk of corneal abrasions,
mucous membrane blistering, oesophagal strictures, kid-
ney problems and cardiomyopathy. Scarring can lead to
difﬁculty eating, vision impairment, painful stools, and
constipation. RDEB patients have a high risk of develop-
ing aggressive squamous cell carcinomas, which is asso-
ciated with early mortality.6
Patients with RDEB-other (RDEB-O) have a similar,
though less severe, phenotype compared to those with
RDEB-GS. They produce some functional, albeit abnor-
mal, C7. They also have a better prognosis, with some
affected women capable of giving birth. RDEB-O patients
are frequently compound heterozygotes: one allele is
a missense, in-frame, or splice site mutation, while
the second often contains a premature stop codon.8,10
Genotype-Phenotype Correlation
RDEB generalized severe cases often result from null
mutations. Most reported null mutations are nonsense or
frameshift mutations that cause premature stop codons, but
others destroy the methionine initiation code or completely
disrupt splicing.11,12 Approximately 12% of RDEB-GS
cases are compound heterozygotes for one premature ter-
mination mutation and one missense mutations, or two
missense mutations.12
Premature stop codons (PTCs) also play a signiﬁcant
role in RDEB-O. In one study, 34% of cases had PTC
mutations in both alleles.12 Over half of the remaining
cases were compound heterozygotes for a PTC mutation
and a missense mutation, primarily glycine substitutions.
Glycine or arginine substitutions in the collagenous
domain appear to cause RDEB inversa (RDEB-I). Some
of these substitutions are speciﬁc to RDEB-I, but others
have also been reported in non-inversa subtypes.13 Cases
with one or two missense mutations usually have
a milder phenotype than those with a PTC mutation.
The presentation may be similar to DDEB in some
cases.11 It is not always clear why a case with two PTC
alleles may present with the milder RDEB-O phenotype.
Exon skipping, resulting in a shortened but functional
protein, explains this phenomenon in some, but not all,
cases.12
Epidemiology
Several authors have reported on the epidemiology of DEB
(Table 1).11,14–17 The incidence of DEB mutations reported
in these studies ranged from 0.2 to 6.65 per million live
births; the prevalence ranged from 3.0 to 20.4 per million
people. All studies used multiple methods of ascertainment,
including records from hospitals, dermatology clinics, pae-
diatricians and general practitioners, newspaper advertise-
ments, announcements in patient newsletters, and family
networks. The two studies that examined ascertainment by
source found that the majority of cases were not followed at
referral centres or recognized as having EB by their primary
care physician, highlighting the difﬁculty of complete
ascertainment.18,19
Methods
In this study, we estimate the incidence of recessive dys-
trophic epidermolysis bullosa cases by leveraging publicly
available whole-exome sequencing (WES) and whole-
genome sequencing (WGS) data to estimate the allele
frequency of recessive pathogenic variants in the
COL7A1 gene among healthy adult carriers.
Pathogenic Genetic Variants Observed in
Cases
We developed an inventory of reported pathogenic COL7A1
variants from ClinVar20 and the DEB Register,12,21 an inter-
national registry for DEB patients and their COL7A1 muta-
tions. The primary goal was to build a model to predict
whether an allele could result in an RDEB phenotype when
harboured in a homozygous state or compound heterozygous
state with another pathogenic allele. To build our model, we
constructed a training data set composed of established
Dovepress Eichstadt et al
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nonpathogenic variants in COL7A1 and variants that were
clearly associated with some form of dystrophic EB. We
classiﬁed alleles as pathogenic for RDEB if the majority of
sources report the allele as causing or associated with RDEB;
DDEB if 50% ormore of the sources report the allele causing
or in association with DDEB; and DEB, not otherwise spe-
ciﬁed (NOS) if no sources report inheritance pattern.
We considered variants as causal if they were consistently
classiﬁed as “Pathogenic” or “Likely Pathogenic” in ClinVar
or the majority of DEB Register participants that carried the
allele had a dystrophic EB phenotype and there was no
conﬂicting evidence in ClinVar. We identiﬁed a total of 86
variants that cause DDEB, 155 variants causing RDEB, and
15 DEB-NOS variants. All variants that were removed from
the training set due to conﬂicting evidence annotations were
retained in the test set and subsequently evaluated for their
potential pathogenic inﬂuence with respect to RDEB.
Population Genetics Database
In order to estimate the allele frequency of pathogenic variants,
we leveraged the Exome Aggregation Consortium (ExAC)
database and the Genome Aggregation Database
(gnomAD).22 ExAC contains over 60,000 genotypes from
14 datasets and is ethnically diverse (Appendix A). The only
individuals excluded from the ﬁnal database are those with
severe pediatric diseases, such as DEB and other genetic
diseases, and those without adequate informed consent. The
inclusion criteria allow for the detection of heterozygous car-
riers of COL7A1 variants, but should exclude affected indivi-
duals with homozygous alleles for pathogenic variants.
Therefore, COL7A1 variants that are homozygous within
ExAC samples are unlikely to be causal for RDEB.
The ExAC database is a subset of gnomAD. GnomAD
contains 123,136 exomes and 15,496 genomes from
healthy human donors. As the ﬁrst degree relatives of
individuals with severe congenital disorders are excluded
in gnomAD, using it risks a downward bias in the esti-
mated allele frequency of pathogenic COL7A1 variants.
Nonetheless, as RDEB is a rare disorder, the likelihood
that any carrier has a ﬁrst degree relative with the disease
is still quite low. Therefore, while we preferentially report
estimates derived from ExAC when a pathogenic variant is
listed in both databases, pathogenic and predicted patho-
genic variants found only in gnomAD are still reported.
Predicted Pathogenic Alleles
We predicted the pathogenicity of previously unclassiﬁed
missense variants observed in whole-exome sequences using
two automated classiﬁers, one for missense mutations and one
for frameshift mutations. The missense classiﬁer predicts
the clinical impact of amino acid substitutions caused by
missense mutations by synthesizing the predictions
from six variant functional prediction tools: FATHMM,23
MutationAssessor,24 PolyPhen-2,25 PROVEAN,18 SIFT,26
and CONDEL.27 Variants for training the model were selected
from variants with known clinical relationships to dystrophic
EB as described in section 2.1.
We ﬁrst compiled a training set of 256 known pathogenic
and 14 known benign missense mutations based on well-
established pathogenic status from ClinVar28 or the DEB
Register.29 We applied six prediction tools to these variants,
and from their scores ﬁtted a multivariable logistic regression
model to predict the disease state of a hypothetical homo-
zygous carrier for a given variant (Figure 1).
Based on the clustering of pathogenic variants and dis-
tribution of prediction scores (Figure 2) in the training data-
base, we classiﬁed variants as pathogenic if the prediction
score was 0.95 or higher. With this cut-point, the model
correctly classiﬁed 14 of 14 benign variants and 225 of 256
pathogenic variants, resulting in a positive predictive value of
100%, sensitivity of 88% and speciﬁcity of 100%. To guard
against the ﬁnal estimate of net pathogenic allele frequency
being biased upward by likely false positives we ﬁltered our
list of previously reported and newly predicted pathogenic
variants to remove variants for which homozygous carriers
are observed in either ExAC or gnomAD (both of which
should only contain unaffected individuals), variants with
low conﬁdence loss of function ﬂags in either sequencing
database, and any variant with an allele frequency greater
than 0.0001 as it would suggest a disease prevalence that is
unrealistically high for this rare disorder.
The splice site classiﬁer predicts the impact of non-coding
variants on intron-exon splicing. The classiﬁer is based on
a logistic regression model, which integrates the functional
annotation scores from the CADD19 and EIGEN28 algorithms
into a composite score. As with the missense classiﬁer, the
predictions from the splice site model are reﬁned using
a maximum cutoff 0.0001 for allele frequency. We applied
the model to a training dataset of 16 known pathogenic
variants and 17 known benign variants. We set the threshold
of pathogenicity conservatively at a composite score of 0.8,
resulting in a sensitivity of 0.44 and a speciﬁcity of 1.
We estimated the net carrier allele frequency as the sum
of the individual pathogenic allele frequencies from the
ExAC database, or when a variant was not found in ExAC,
from the larger gnomAD database. We calculated the
Eichstadt et al Dovepress
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frequency estimates for pathogenic alleles using all available
genotypes in each respective database, as we found no differ-
ences in the net carrier allele frequency by ancestry.
The assumption was made that individuals with two
null alleles would have RDEB-GS and those with any
other two pathogenic alleles would have RDEB-O. We
estimated genotype frequency from observed allele fre-
quencies assuming homozygote/heterozygote proportions
expected under Hardy–Weinberg equilibrium.
The incidence of RDEB was estimated as the number of
births in the US per year times the total expected frequency
of pathogenic genotypes. Next, the number of cases per
group were summed to get the total number of cases for
a birth cohort.29We estimated prevalence using the estimated
number of cases born in a birth cohort and the cumulative
probability of death for RDEB subtype (Table 2).30 The
calculations were done using cases born in 1960 or later.
Results
Frequency of RDEB Variants
The ExAC and gnomAD databases contained 1620 COL7A1
exonic variants that cause amino acid substitutions absent in
our training set. In total, 523 variants were classiﬁed as patho-
genic for RDEB, encompassing 193 previously reported
pathogenic variants, including 5 dominant mutations. The
variants included 128 premature termination codons, 323
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Figure 1 Model Classiﬁcation of Training Data. The 3D scatter plot shown here demonstrates the ability of the classiﬁer and three components to stratify the variants into
similar functional clusters.
Figure 2 Distribution of Pathogenicity Scores in Training Data.
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missense and 67 splice site mutations. The vast majority of
both known and predicted pathogenic alleles had frequencies
of less than the 0.0001 inclusion criteria (Figure 3). In all, we
excluded 12 variants from our ﬁnal inventory of pathogenic
variants (2 previously reported and 10 newly predicted patho-
genic alleles) whose observed allele frequencies exceeded this
cutoff.
After adjusting the model to account for the overrepresen-
tation of pathogenic variants in the training dataset, variant
classiﬁcation was more conservative and less sensitive to the
threshold used to classify a variant as pathogenic (Table 3). To
adjust for the pathogenic over-representation in the training
set, we ﬁrst estimated the true proportion of pathogenic var-
iants in the population. We estimate this proportion as
a function of the mean pathogenicity scores as follows:
p ¼ ðuu  ubÞðup  ubÞ
Where
µb = mean composite score of the benign variants;
µp = mean composite score of the pathogenic variants;
µu = mean composite score of the unclassiﬁed var-
iants; and
p = proportion of pathogenic variants in the unclassi-
ﬁed set
We then performed weighted logistic regression simi-
lar to the methods previously described by Rose et al32
Since we are controlling for an overrepresentation of
variants as opposed to patients, we modiﬁed Rose’s
approach by treating pathogenic variants as cases, benign
variants as controls, and the weight for each variant as
the ratio of the proportion of the variant class in the
unclassiﬁed set to the proportion of the variant class in
the training set. After adjusting the model to account for
the overrepresentation of pathogenic variants in the train-
ing dataset, variant classiﬁcation was more conservative
and less sensitive to the threshold used to classify
a variant as pathogenic (Table 3). The adjustment also
resulted in less dispersal in the distribution of the patho-
genicity scores.
We further explored whether the performance of the
bias-corrected model varied due to the choice of benign
and pathogenic variants in the training datasets using
3-fold cross-validation. We divided the training datasets
of known benign and pathogenic variants into three dis-
tinct subsets. In each of the three cross-validations, two
subsets formed the training dataset and one subset formed
the testing dataset. Because the number of benign variants
(n=14) and pathogenic variants (n=256) are not divisible
by three, 2 of 3 cross-validation testing datasets will con-
tain ﬁve benign variants and one testing dataset will con-
tain only four benign variants, with an additional
pathogenic variant. We conducted 100 iterations of the
3-fold cross-validation, maintaining the same weights and
pathogenicity score cutoff (0.95) for each cross-validation.
For each iteration of the 3-fold cross-validation, we calcu-
lated the sensitivity, speciﬁcity, positive predictive value
and negative predictive value of the model. We also cal-
culated the average sensitivity, speciﬁcity, positive predic-
tive value and negative predictive value across all 100
iterations.
Approximately 4 million infants are born in the United
States annually.33 Based on this number of births and the
frequency of pathogenic allele variants, we estimate that
251 infants with RDEB are born each year in the US
(Table 4). Of these, 10 are predicted to have the severe
form of RDEB. During the last decade, the European
Union averaged a total of 5.23 million births per year.33
Based on the above frequency of RDEB pathogenic
alleles, an estimated 326 cases of RDEB are born in the
European Union each year, of which 13 are predicted to be
RDEB-GS (Table 4).
Applying life table analysis to the number of cases born
per year, an estimated 12,562 individuals affected with
RDEB who were born since 1960 are living in the US,
and 16,290 are living in the European Union (Table 5).
Table 2 Cumulative Probability of Mortality by Age and RDEB
Subtype
Age Cumulative Probability of Mortality
RDEB-GS RDEB-O
1 0.0101 0.0058
2 0.0101 0.0058
5 0.0101 0.0058
10 0.0218 0.0058
15 0.0474 0.0299
20 0.1584 0.0299
25 0.2899 0.0810
30 0.3867 0.1003
35 0.5912 0.1723
40 0.7664 0.2061
45 0.7664 0.2557
50 0.7664 0.2557
55 0.7664 0.3550
60 0.7664 0.3550
Note: Deﬁnitions from Fine.31
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Fewer than 2% of those individuals are predicted to have the
RDEB-GS subtype.
Simulation
Given the challenges noted in clinical RDEB
ascertainment,18,19 we further performed a Monte Carlo
simulation to estimate the expected number of RDEB cases
who may beneﬁt from COL7A1-mediated treatments (e.g.,
gene therapy, gene editing, mRNA) using MATLAB® and
Simulink®. The Monte Carlo method uses computational
algorithms based on iterations of random sampling from
a positively skewed probability distribution (i.e., the prob-
ability is inversely related to larger population-based infer-
ences versus known validated patient registries) in order to
acquire numerical results for the goals of sampling, optimi-
zation, and estimations.34–36 In other words, our population
conﬁdence decreased as we increased our reliance on sequen-
cing point estimates, resulting in positive skewness for the
probability distribution. Using a minimum amount deﬁned as
the mean of RDEB-GS of 343 and a maximum population
estimate of 12,562 of any RDEB, we conducted 10,000
repetitions resulting in a mean estimate of approximately
3850 patients in the US who may beneﬁt from COL7A1-
mediated treatments in the US.
Discussion
Genetic modelling applied to the whole exome and genome
sequencing data resulted in the identiﬁcation of predicted
RDEB pathogenic alleles, from which our estimate of the
incidence of RDEB is 95 per million live births, 30 times the
3.05 per million live birth incidence estimated by the National
Epidermolysis Bullosa Registry (NEBR). The NEBR may
have under-ascertained less severely affected cases, because
at least two studies have reported that amajority of the cases in
their studies were not evaluated and treated at EB referral
centres.18,19 Alternatively, we may have overestimated the
incidence of RDEB. Our estimates are based on allele fre-
quencies, not clinical symptoms. Also, while a robust database
of pathogenic mutations is available, there are a limited num-
ber of benign missense mutations available23 to utilize as
Figure 3 Distribution of Allele Frequencies.
Table 3 Allele Frequency of DEB Pathogenic Variants in Col7A1 Gene
DEB Type Number of Distinct
Variants
Count of Variant
Alleles
Allele
Frequency
95% Conﬁdence
Interval
Dominant 5 7 5.11E-05 0.0000248, 0.0001055
Premature termination or frameshift 128 177 0.001598 0.0013794, 0.0018510
Missense 234 606 0.005268 0.0048660, 0.0057033
Splice site 67 112 0.000974 0.0007684, 0.0011121
All variants* 434 902 0.007842 0.0073481, 0.0083681
Note: *Individual variant type frequencies do not total to the frequency of all variants due to adjustment for different denominators.
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a training set. The pathogenicity of splice site mutations is also
difﬁcult to predict, making them particularly susceptible to
misclassiﬁcation; even though a conservative threshold was
used, some benign variants may be misclassiﬁed as patho-
genic. Our methodology also overestimates the incidence of
RDEB for those genotypes that are incompletely penetrant37
and if fetuses with RDEB are at an increased risk of fetal
death. DEB is a complex disorder; clinical symptomsmanifest
along a continuum of mild to extremely severe. Genotype
does not always predict either protein function or disease
severity well.13 Our estimates of incidence and prevalence
apply to a range of RDEB phenotypes and may be limited in
the ability to estimate the prevalence of speciﬁc symptoms.
A further complication to estimating the incidence of
RDEB is the reproductive potential of moderately affected
patients. Shinkuma6 noted that some RDEB-GO patients
are capable of giving birth, but we did not ﬁnd any
information on male fertility in RDEB patients. The meth-
odology we used assumes alleles are in Hardy–Weinberg
equilibrium. It remains valid if cases of either sex repro-
duce, as long as this assumption is met. Notwithstanding,
consensus panels recognize that RDEB-GO is a diverse
group of RDEB subtypes ranging from RDEB generalized
intermediate, RDEB pruiginosa, RDEB bullous dermolysis
of the newborn, RDEB pretibial, RDEB centripetalis,
RDEB inversa and RDEB localized which may be
explored further.38
Conclusion
In sum, this study evaluates the incidence and prevalence
of RDEB using publicly available whole-exome sequen-
cing and whole-genome sequencing databases. We estab-
lished a range estimate, as well as a simulation model, of
RDEB patients who may beneﬁt from COL7A1-directed
treatments. We conclude that genetic allele frequency esti-
mation may enhance the underdiagnosis of rare genetic
diseases generally, and RDEB speciﬁcally, which may
improve incidence and prevalence estimates of patients
who may beneﬁt from treatment.
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